PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMV Pharmaceuticals (PMVP), a precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53, has announced its participation in two upcoming investor conferences. The company's management, including CEO David H. Mack and Chief Development Officer Deepika Jalota, will present at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 11:30 AM EDT, and the Jefferies Global Healthcare Conference on June 5, 2025, at 3:45 PM EDT. Both presentations will be available via live audio webcast, with replays accessible for 90 days afterward.
PMV Pharmaceuticals (PMVP), un'azienda di oncologia di precisione specializzata nello sviluppo di terapie tumorali agnostiche basate su piccole molecole che mirano a p53, ha annunciato la sua partecipazione a due prossimi convegni per investitori. Il management dell'azienda, incluso il CEO David H. Mack e la Chief Development Officer Deepika Jalota, presenterà al TD Cowen 6th Annual Oncology Innovation Summit il 27 maggio 2025 alle 11:30 EDT, e al Jefferies Global Healthcare Conference il 5 giugno 2025 alle 15:45 EDT. Entrambe le presentazioni saranno trasmesse in diretta audio via webcast, con repliche disponibili per 90 giorni successivi.
PMV Pharmaceuticals (PMVP), una empresa de oncología de precisión enfocada en desarrollar terapias tumorales agnósticas basadas en pequeñas moléculas dirigidas a p53, ha anunciado su participación en dos próximas conferencias para inversores. La dirección de la empresa, incluyendo al CEO David H. Mack y a la Directora de Desarrollo Deepika Jalota, presentará en el TD Cowen 6th Annual Oncology Innovation Summit el 27 de mayo de 2025 a las 11:30 AM EDT, y en la Jefferies Global Healthcare Conference el 5 de junio de 2025 a las 3:45 PM EDT. Ambas presentaciones estarán disponibles en transmisión en vivo por audio webcast, con repeticiones accesibles durante 90 días después.
PMV Pharmaceuticals (PMVP)는 p53을 표적으로 하는 종양-비특이적 소분자 치료제를 개발하는 정밀 종양학 회사로서, 다가오는 두 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사 경영진인 CEO David H. Mack와 최고개발책임자 Deepika Jalota가 TD Cowen 6th Annual Oncology Innovation Summit에 2025년 5월 27일 오전 11시 30분(동부시간) 그리고 Jefferies Global Healthcare Conference에 2025년 6월 5일 오후 3시 45분(동부시간)에 발표할 예정입니다. 두 발표 모두 라이브 오디오 웹캐스트로 제공되며, 이후 90일간 다시보기 가능합니다.
PMV Pharmaceuticals (PMVP), une société d'oncologie de précision spécialisée dans le développement de thérapies tumorales agnostiques ciblant p53 à base de petites molécules, a annoncé sa participation à deux prochaines conférences pour investisseurs. La direction de l'entreprise, comprenant le PDG David H. Mack et la directrice du développement Deepika Jalota, présentera lors du TD Cowen 6th Annual Oncology Innovation Summit le 27 mai 2025 à 11h30 EDT, ainsi qu'à la Jefferies Global Healthcare Conference le 5 juin 2025 à 15h45 EDT. Les deux présentations seront diffusées en direct en webcast audio, avec des rediffusions accessibles pendant 90 jours ensuite.
PMV Pharmaceuticals (PMVP), ein Unternehmen für Präzisionsonkologie, das sich auf die Entwicklung von tumor-agnostischen Kleinmolekültherapien mit Ziel auf p53 spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Management des Unternehmens, einschließlich CEO David H. Mack und Chief Development Officer Deepika Jalota, wird auf dem TD Cowen 6th Annual Oncology Innovation Summit am 27. Mai 2025 um 11:30 Uhr EDT und auf der Jefferies Global Healthcare Conference am 5. Juni 2025 um 15:45 Uhr EDT präsentieren. Beide Präsentationen werden als Live-Audio-Webcast verfügbar sein, mit Wiederholungen, die anschließend für 90 Tage abrufbar sind.
- None.
- None.
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.
TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Date: Tuesday, May 27, 2025
Time: 11:30 AM EDT
Jefferies Global Healthcare Conference
Date: Thursday, June 5, 2025
Time: 3:45 PM EDT
A live audio webcast of the events will be available online at Events & Presentations. An archived replay of PMV Pharma’s presentations will be available for 90 days following the webcast at Events & Presentations.
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
FAQ
When is PMV Pharmaceuticals (PMVP) presenting at the TD Cowen Oncology Summit 2025?
What time is PMVP's presentation at the Jefferies Global Healthcare Conference 2025?
Who will represent PMV Pharmaceuticals at the upcoming investor conferences?
How long will the webcast replays be available for PMVP's conference presentations?
